Clinical Trial Update: Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A phase 2 study of galunisertib in combination with enzalutamide for metastatic castration-resistant prostate cancer; the trial is currently active but not recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• Galunisertib (galunisertib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING